Antihypertensive effect of irbesartan and predictors of response in obesity-associated hypertension: A prospective, open-label study

Clinical Drug Investigation

Volumn 25, Issue 12, 2005, Pages 765-776

  Sharma, Arya M ^a   Bramlage, Peter ^b   Kirch, Wilhelm ^b  

^a MCMASTER UNIVERSITY   (Canada)

^b DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

IRBESARTAN;

ADULT; AGED; ANGIONEUROTIC EDEMA; ARTICLE; BLOOD PRESSURE; BLOOD PRESSURE REGULATION; BODY MASS; BODY WEIGHT; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DIASTOLIC BLOOD PRESSURE; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG TOLERABILITY; FATIGUE; FEMALE; HEADACHE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; MYALGIA; NAUSEA; OBESITY; PHYSICIAN; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; SYSTOLIC BLOOD PRESSURE; VERTIGO; WAIST CIRCUMFERENCE;

EID: 28444477333     PISSN: 11732563     EISSN: 11732563     Source Type: Journal    
DOI: 10.2165/00044011-200525120-00003     Document Type: Article

References (36)

1. Kopelman PG. Obesity as a medical problem. Nature 2000; 404 (6778): 635-43
2. Bramlage P, Pittrow D, Wittchen HU, et al. Hypertension in overweight and obese primary care patients is highly prevalent and poorly controlled. Am J Hypertens 2004; 17 (10): 904-10
3. Mokdad AH, Serdula MK, Dietz WH, et al. The spread of the obesity epidemic in the United States, 1991-1998. JAMA 1999; 282 (16): 1519-22
4. National Institutes of Health. Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults: The Evidence Report. Obes Res 1998; 6 Suppl. 2: 51-209S
5. Brown CD, Higgins M, Donato KA, et al. Body mass index and the prevalence of hypertension and dyslipidemia. Obes Res 2000; 8 (9): 605-19
6. Dyer AR, Elliott P, Shipley M. Body mass index versus height and weight in relation to blood pressure: findings for the 10,079 persons in the INTERSALT Study. Am J Epidemiol 1990; 131 (4): 589-96
7. MacMahon S, Cutler J, Brittain E, et al. Obesity and hypertension: epidemiological and clinical issues. Eur Heart J 1987; 8 Suppl. B: 57-70
8. Pischon T, Sharma AM. Optimizing blood pressure control in the obese patient. Curr Hypertens Rep 2002; 4 (5): 358-62
9. Sharma AM. Is there a rationale for angiotensin blockade in the management of obesity hypertension? Hypertension 2004; 44 (1): 12-9
10. Sharma AM, Janke J, Gorzelniak K, et al. Angiotensin blockade prevents type 2 diabetes by formation of fat cells. Hypertension 2002; 40: 609-11
11. Huang XR, Chen WY, Truong LD, et al. Chymase is upregulated in diabetic nephropathy: implications for an alternative pathway of angiotensin II-mediated diabetic renal and vascular disease. J Am Soc Nephrol 2003; 14 (7): 1738-47
12. Voors AA, Oosterga M, Buikema H, et al. Differences between angiotensin-converting enzyme inhibition and angiotensin II-AT1 antagonism on angiotensin-mediated responses in human internal mammary arteries. J Cardiovasc Pharmacol 2003; 41 (2): 178-84
13. Waeber B, Burnier M. AT1-receptor antagonism in hypertension: what has been learned with irbesartan? Expert Rev Cardiovasc Ther 2003; 1 (1): 23-33
14. Markham A, Spencer CM, Jarvis B. Irbesartan: an updated review of its use in cardiovascular disorders. Drugs 2000; 59 (5): 1187-206
15. Montalescot G, Collet JP. Preserving cardiac function in the hypertensive patient: why renal parameters hold the key. Eur Heart J. Epub 2005 Jul 18
16. Croom KF, Curran MP, Goa KL, et al. Irbesartan: a review of its use in hypertension and in the management of diabetic nephropathy. Drugs 2004; 64 (9): 999-1028
17. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345 (12): 851-60
18. Parving HH, Lehnert H, Brochner-Mortensen J, et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001; 345 (12): 870-8
19. Knight EL, Bohn RL, Wang PS, et al. Predictors of uncontrolled hypertension in ambulatory patients. Hypertension 2001; 38 (4): 809-14
20. Gueyffier F, Bulpitt C, Boissel JP, et al. Antihypertensive drugs in very old people: a subgroup meta-analysis of randomised controlled trials. INDANA Group. Lancet 1999; 353 (9155): 793-6
21. Scottish Intercollegiate Guidelines Network (SIGN). Hypertension in older people [online]. SIGN Publication 49. Edinburg, UK. Available from URL: http://www.sign.ac.uk/guidelines/fulltext/49/. [Accessed 2005 9 Nov]
22. Guidelines committee. European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003; 21: 1011-53
23. Reaven GM, Lithell H, Landsberg L. Hypertension and associated metabolic abnormalities: the role of insulin resistance and the sympathoadrenal system. N Engl J Med 1996; 334 (6): 374-81
24. Rahmouni K, Correia ML, Haynes WG, et al. Obesity-associated hypertension: new insights into mechanisms. Hypertension 2005; 45 (1): 9-14
25. Parish JM, Somers VK. Obstructive sleep apnea and cardiovascular disease. Mayo Clin Proc 2004; 79 (8): 1036-46
26. Hall JE. The kidney, hypertension, and obesity. Hypertension 2003; 41 (3 Pt 2): 625-33
27. Aronne LJ. Classification of obesity and assessment of obesity-related health risks. Obes Res 2002; 10 (90002): 105S-15
28. Gill T, Chittleborough C, Taylor A, et al. Body mass index, waist hip ratio, and waist circumference: which measure to classify obesity? Soz Praventivmed 2003; 48 (3): 191-200
29. Lehnert H, Wittchen HU, Pittrow D, et al. Prevalence and pharmacotherapy of diabetes mellitus in primary care [in German]. Dtsch Med Wochenschr 2005; 130 (7): 323-8
30. Pittrow D, Kirch W, Bramlage P, et al. Patterns of antihypertensive drug utilization in primary care. Eur J Clin Pharmacol 2004; 60: 135-42
31. Ferrari P, Hess L, Pechere-Bertschi A, et al. Reasons for not intensifying antihypertensive treatment (RIAT): a primary care antihypertensive intervention study. J Hypertens 2004; 22 (6): 1221-9
32. Bramlage P, Pittrow D, Kirch W. The effect of irbesartan in reducing cardiovascular risk in hypertensive type 2 diabetic patients: an observational study in 16 600 patients in primary care. Curr Med Res Opin 2004; 20 (10): 1625-31
33. Lehnert H, Bramlage P, Pittrow D, et al. Regression of microalbuminuria in type 2 diabetics after switch to irbesartan treatment: an observational study in 38016 patients in primary care. Clin Drug Invest 2004; 24 (4): 217-25
34. Benson K, Hartz AJ. A comparison of observational studies and randomized, controlled trials. N Engl J Med 2000; 342 (25): 1878-86
35. Claxton A, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther 2001; 23 (8): 1296-310
36. Hasford J, Mimran A, Simons W. A population-based European cohort study of persistence in newly diagnosed hypertensive associpatients. J Hum Hypertens 2002; 16 (8): 569-75